Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23998022 | 0.98 | NPSR1 (0.35) | NPSR1CA1CA2CA12CA9 | |
| SCHEMBL25612292 | 0.90 | — | — | |
| SCHEMBL31723183 | 0.83 | NPSR1 (0.35) | NPSR1CA1CA2CA12CA9 | |
| SCHEMBL23030178 | 0.79 | NPSR1 (0.33) | NPSR1CA1CA2CA12CA9 | |
| SCHEMBL22281712 | 0.79 | NPSR1 (0.33) | NPSR1CA1CA2CA12CA9 | |
| SCHEMBL14623174 | 0.79 | — | — | |
| SCHEMBL1355932 | 0.79 | — | — | |
| SCHEMBL10396015 | 0.78 | ACACB (0.33) | — | |
| SCHEMBL1355923 | 0.77 | NPSR1 (0.37) | NPSR1CA1CA2CA12CA9 | |
| SCHEMBL16281538 | 0.77 | NPSR1 (0.37) | NPSR1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | AMGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | AMGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | AMGEN INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | AMGEN INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | NPSR1 3951/4885CA1 3530/4885CA2 3901/4885 |
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | MCL1, BCL2A1, BAK1 | NPSR1 1884/4885CA1 2510/4885CA2 4481/4885 |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | MCL1, BCL2A1, BAK1 | NPSR1 2082/4885CA1 2891/4885CA2 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.